X4 Pharmaceuticals to host virtual investor day on mavorixafor in chronic neutropenia

XFOR•2026-10-09

X4 Pharmaceuticals will host a virtual investor day on Oct. 29, 2026, focused on mavorixafor in chronic neutropenia, including an update on its Phase 3 4WARD trial and plans for a Phase 2 combination trial.

1. Investor day agenda

X4 Pharmaceuticals will host the event from 10:00 a.m. to 12:00 p.m. ET on Oct. 29, 2026. Management plans to discuss the status of the Phase 3 4WARD trial and outline a Phase 2 trial combining mavorixafor with G-CSF to assess G-CSF dose reduction.

X4 Pharmaceuticals to host virtual investor day on mavorixafor in chronic neutropenia

1. Investor day agenda

Related News

Ocular Therapeutix grants inducement equity awards to 15 new hires under 2019 plan

Hudbay Minerals target price raised to C$40 from C$35

Ameris Bancorp: Truist Securities cuts target price to $84 from $90

Netflix restructuring could affect about 5% of employees, reportedly as early as next week

LCR Ventures says UK health-tech founders face tougher NHS traction scrutiny as Q2 2026 biotech funding hits £2.05 billion